In US and Canada Call Toll Free: (877) 597-9236
Everywhere Else Call: (760) 431-6300


2020 CRISPR Gene/Genome Editing Dashboard Series 1 – NA & EU -

2020 CRISPR Dashboard Series 1 - NA-EUCatalog number: 2006CRI
Publication date: June 2020
Single Site License*: $3,975
Small Company/ Start-up**: $2,395
Enterprise Wide/ Multi-site: $6,500

*Single Site License is intended for companies with only one physical location. Please order these copies directly with Percepta Associates

**Small company/Start-up pricing is intended for small companies, of 40 or less employees. Please order these copies directly with Percepta Associates

CRISPR technology is a simple yet powerful tool for editing genomes. It allows researchers to easily alter DNA sequences and modify gene function. Its many potential applications include correcting genetic defects, treating and preventing the spread of diseases and improving crops. As life science suppliers continue to improve products and services the CRISPR gene/genome editing market, represents a significant opportunity within the life sciences industry.

Percepta’s 2020 CRISPR Gene/Genome Editing Life Science Dashboard™ is the first in a series that characterizes the dynamic market for products for CRISPR experiments.

This 2020 Dashboard provides a snapshot of the current market landscape, with the future goal of repeating and publishing the study to give Dashboard readers the ongoing story of how the market is adapting to new products, new competitors and new sales and marketing strategies.

The 2020 CRISPR Gene/Genome Editing Dashboard™ was developed from responses to a 29-question survey completed by 368 scientists located in North America and Europe. This Dashboard reveals key market indicators for the CRISPR market as a whole as well as for the following techniques representing market sub-segments:

  • Cas9 protein (e.g. Cas9/Cas12a nucleases, Cas9-nickase)
  • Cas9 mRNA
  • Guide RNA (synthetic)
  • Guide RNA (in vitro transcribed)
  • CRISPR libraries/library pools
  • CRISPR/Cas9 plasmid/mammalian expression systems
  • CRISPR/Cas9 viral/viral delivery systems (e.g. lentivirus, AAV)
  • HDR knockin reagents (e.g. ssDNA, oligos, plasmids)
  • Immunologic CRISPR detection tools (e.g. antibody, ELISA, FACS)
  • Kits/products for detection of editing (e.g. indel/editing/cleavage detection)

This report is focused on the use of CRISPR gene/genome editing products in the life science research market.

The following suppliers were surveyed for this report:

  • Abcam
  • Addgene
  • Agilent/Stratagene
  • Applied Biological Materials (ABM)
  • BioLegend
  • BioTechne/Novus/R&D Systems
  • Cell Signaling Technologies
  • Diagenode
  • Epigentek
  • GeneCopoeia
  • GenScript
  • Horizon Discovery/Dharmacon
  • Integrated DNA Technologies (IDT)
  • Millipore/Sigma Aldrich/Merck
  • New England Biolabs
  • Origene
  • Promega
  • Santa Cruz Biotechnology
  • Synthego
  • Clontech/Takara
  • Thermo Fisher Scientific/Life Technologies/Invitrogen/Ambion/Pierce
  • Twist Bioscience

5          Executive Summary

8          Dashboard “At A Glance”

15         Market Opportunity Matrix

13         Respondents Qualification

15         Demographics

22         Frequency of Performance: Life Science Techniques

26         Frequency of Use: CRISPR Gene / Genome Editing

52         Co-Performance: CRISPR Gene / Genome Editing Experiments & Life Science Techniques

55         Throughput, Growth Rates, Price & Monthly Spend

65         Market Size

67         Percent of Spend with Suppliers by Segment (Share of Budget)

94         Customer Satisfaction & Interest in Switching

98          Purchase Decision Factors: Product Features

102         Primary Downstream Application

106         Desired Product Changes

118          Appendix I: Supporting Data

130         Appendix II: Percepta Capabilities and Life Science Dashboards™ Available

2020 CRISPR Gene/Genome Editing Dashboard Series 1 – NA & EU

  • This field is for validation purposes and should be left unchanged.

Available upon request

Copyright © 2024 Percepta Associates Inc. All rights reserved. Terms & Conditions.